Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study by Clark, Andrew et al.
www.thelancet.com/lancetgh   Vol 8   August 2020 e1003
Articles
Lancet Glob Health 2020; 
8: e1003–17
Published Online 
June 15, 2020 
https://doi.org/10.1016/
S2214-109X(20)30264-3
See Comment page e974
*Members are listed in the 
appendix
Department of Health Services 
Research and Policy 
(A Clark PhD, 
Prof C Sanderson PhD, 
Prof M McKee DSc), Department 
of Infectious Disease 
Epidemiology (Prof M Jit PhD, 
Prof F Checchi PhD, 
H P Gibbs MSc, R M Eggo PhD), 
and Department of Non-
Communicable Disease 
Epidemiology 
(C Warren-Gash PhD, 
Prof P Perel PhD), London 
School of Hygiene & Tropical 
Medicine, London, UK; Centre 
for Population Health Sciences, 
Usher Institute, University of 
Edinburgh, Edinburgh, UK 
(Prof B Guthrie PhD, 
Prof S W Mercer PhD); School of 
Public Health, Sun Yat-Sen 
University, Guangzhou, China 
(H H X Wang PhD); Department 
for Health Metrics 
(C Troeger MPH) and Institute 
for Health Metrics and 
Evaluation (K L Ong PhD), 
University of Washington, 
Seattle, WA, USA; IAVI Human 
Immunology Laboratory, 
Imperial College London, 
London, UK (S Joseph PhD); and 
Institute of Health Informatics, 
University College London, 
London, UK (A Banerjee DPhil)
Correspondence to: 
Dr Andrew Clark, Department of 
Health Services Research and 
Policy, London School of Hygiene 
& Tropical Medicine, London 
WC1E 7HT, UK 
andrew.clark@lshtm.ac.uk
See Online for appendix
Global, regional, and national estimates of the population at 
increased risk of severe COVID-19 due to underlying health 
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Summary
Background The risk of severe COVID-19 if an individual becomes infected is known to be higher in older individuals 
and those with underlying health conditions. Understanding the number of individuals at increased risk of severe 
COVID-19 and how this varies between countries should inform the design of possible strategies to shield or vaccinate 
those at highest risk.
Methods We estimated the number of individuals at increased risk of severe disease (defined as those with at least one 
condition listed as “at increased risk of severe COVID-19” in current guidelines) by age (5-year age groups), sex, and 
country for 188 countries using prevalence data from the Global Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) 2017 and UN population estimates for 2020. The list of underlying conditions relevant to COVID-19 was 
determined by mapping the conditions listed in GBD 2017 to those listed in guidelines published by WHO and public 
health agencies in the UK and the USA. We analysed data from two large multimorbidity studies to determine 
appropriate adjustment factors for clustering and multimorbidity. To help interpretation of the degree of risk among 
those at increased risk, we also estimated the number of individuals at high risk (defined as those that would require 
hospital admission if infected) using age-specific infection–hospitalisation ratios for COVID-19 estimated for 
mainland China and making adjustments to reflect country-specific differences in the prevalence of underlying 
conditions and frailty. We assumed males were twice at likely as females to be at high risk. We also calculated the 
number of individuals without an underlying condition that could be considered at increased risk because of their 
age, using minimum ages from 50 to 70 years. We generated uncertainty intervals (UIs) for our estimates by running 
low and high scenarios using the lower and upper 95% confidence limits for country population size, disease 
prevalences, multimorbidity fractions, and infection–hospitalisation ratios, and plausible low and high estimates for 
the degree of clustering, informed by multimorbidity studies.
Findings We estimated that 1·7 billion (UI 1·0–2·4) people, comprising 22% (UI 15–28) of the global population, have 
at least one underlying condition that puts them at increased risk of severe COVID-19 if infected (ranging from <5% of 
those younger than 20 years to >66% of those aged 70 years or older). We estimated that 349 million (186–787) people 
(4% [3–9] of the global population) are at high risk of severe COVID-19 and would require hospital admission if 
infected (ranging from <1% of those younger than 20 years to approximately 20% of those aged 70 years or older). We 
estimated 6% (3–12) of males to be at high risk compared with 3% (2–7) of females. The share of the population at 
increased risk was highest in countries with older populations, African countries with high HIV/AIDS prevalence, and 
small island nations with high diabetes prevalence. Estimates of the number of individuals at increased risk were most 
sensitive to the prevalence of chronic kidney disease, diabetes, cardiovascular disease, and chronic respiratory disease.
Interpretation About one in five individuals worldwide could be at increased risk of severe COVID-19, should they 
become infected, due to underlying health conditions, but this risk varies considerably by age. Our estimates are 
uncertain, and focus on underlying conditions rather than other risk factors such as ethnicity, socioeconomic 
deprivation, and obesity, but provide a starting point for considering the number of individuals that might need to be 
shielded or vaccinated as the global pandemic unfolds.
Funding UK Department for International Development, Wellcome Trust, Health Data Research UK, Medical 
Research Council, and National Institute for Health Research.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Emerging evidence from China, Europe, and the USA 
has shown a consistently higher risk of severe COVID-19 
in older individuals and those with underlying health 
conditions.1–3 Severe disease is defined by WHO as “a 
patient with severe acute respiratory illness (fever and at 
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least one sign/symptom of respiratory disease, e.g., cough, 
shortness of breath; AND requiring hospitalization)”.4,5 
In a recent report from the USA, underlying conditions 
were reported in 71% (732/1037) of individuals admitted 
to hospital with COVID-19 and in 94% (173/184) of 
deaths.1 WHO, along with public health agencies in 
countries such as the UK and the USA, have issued 
guidelines on who is considered to be at increased risk of 
severe COVID-19.6–8 This includes individuals with 
cardiovascular disease, chronic kidney disease, diabetes, 
chronic respiratory disease, and a range of other chronic 
conditions. Such conditions increase the risk of needing 
hospital-based treatment such as oxygen supplemen-
tation. A large proportion of the additional health-care 
burden of COVID-19 epidemics is likely to result from 
infection of those with underlying conditions.
Identifying at-risk populations is important not only 
for making projections of the probable health burden in 
countries,9,10 but also for the design of effective strategies 
that aim to reduce the risk of transmission to people in 
target groups. This is sometimes termed shielding, 
defined by WHO11 as “measures to protect vulnerable 
persons at increased risk of severe disease from 
COVID-19...or increased risk of infection”—eg, by 
minimising interactions between individuals at increased 
risk and others. The specific definition of shielding can 
vary from one country to the next, but in general it has 
the potential to reduce mortality in susceptible groups 
(direct benefits), while at the same time mitigating the 
expected surge in demand for hospital beds (indirect 
benefits). However, trying to shield an excessive 
proportion of a population can strain country resources 
and reduce the overall effectiveness of shielding. A 
detailed assessment of the number of at-risk individuals 
can inform possible shielding strategies. If a vaccine 
becomes available in the future, it could also be used to 
inform the number of people with underlying conditions 
who would need to be vaccinated.
The aim of this analysis is to provide global, regional, 
and national estimates of the number of individuals at 
increased risk of severe COVID-19 as a result of their 
underlying medical conditions during 2020.
Methods
Prevalence of underlying health conditions
We mapped the conditions listed in the Global Burden of 
Diseases, Risk Factors, and Injuries Study (GBD)12 to lists 
of conditions associated with increased risk of severe 
COVID-19 from guidelines published by WHO and 
agencies in the UK and USA.6–8 The mapping was 
completed by a clinical epidemiologist (CW-G). Prevalence 
estimates were extracted by age, sex, and country and 
grouped into the following 11 categories: (1) cardiovascular 
disease, including cardio vascular disease caused by 
hypertension; (2) chronic kidney disease, including 
chronic kidney disease caused by hypertension; (3) chronic 
respiratory disease; (4) chronic liver disease; (5) diabetes; 
(6) cancers with direct immunosuppression; (7) cancers 
without direct immuno suppression, but with possible 
immunosup pression caused by treatment; (8) HIV/AIDS; 
(9) tubercu losis (excluding latent infections); (10) chronic 
neurological disorders; and (11) sickle cell disorders. A full 
list of GBD causes included in these categories is shown in 
the appendix (p 2).
We estimated the current number of individuals with 
underlying conditions making them at risk of severe 
COVID-19 by age (5-year age groups), sex, and country 
for 188 countries. Data on the prevalence of underlying 
Research in context
Evidence before this study
As the COVID-19 pandemic evolves, countries are considering 
policies to protect those at increased risk of severe disease. 
This can involve policies to suppress transmission in the wider 
population, vaccination (if a vaccine becomes available), or 
so-called shielding—ie, specific measures to protect those at 
increased risk by minimising interactions between individuals 
at increased risk and others. Guidelines on who is currently 
believed to be at increased risk of severe COVID-19 have been 
published online by WHO and public health agencies in the UK 
and the USA. We searched PubMed using the terms “risk 
factors” AND “COVID-19” without language restrictions, from 
database inception until April 5, 2020, and identified 
62 studies published between Feb 15 and March 20, 2020. 
Evidence from China, Europe, and the USA indicates that older 
individuals, males, and those with underlying conditions such 
as cardiovascular disease and diabetes are at increased risk of 
severe COVID-19 and death. At the time of the search, none of 
the studies identified aimed to quantify the number of 
individuals at increased risk due to underlying health 
conditions.
Added value of this study
This study combines evidence from large international 
databases and new analyses of large multimorbidity studies to 
inform policy makers about the number of individuals that 
might be at increased risk or high risk of severe COVID-19 in 
different countries. We developed a tool for rapid assessments 
of the number and percentage of country populations that 
would need to be targeted under different policies to protect 
those at increased risk.
Implications of all the available evidence
Estimating the number of people at increased risk of severe 
COVID-19 is crucial to help countries to design more effective 
interventions to protect vulnerable individuals and reduce 
pressure on health systems. This information can also inform a 
broader assessment of the health, social, and economic 
implications of shielding various groups.
Articles
www.thelancet.com/lancetgh   Vol 8   August 2020 e1005
conditions were extracted by age, sex, and country from 
GBD 2017 using the GBD results tool and combined 
with UN mid-year population estimates for 2020 for the 
188 countries available.13 Countries were grouped by UN 
geographical regions.14 For this part of the analysis, older 
individuals without underlying conditions were not 
considered to be at increased risk.
Asthma is relatively common, and only moderate to 
severe asthma is listed as an increased-risk condition in 
guidelines in the USA, so we modified GBD estimates of 
asthma to account only for moderate to severe cases 
(defined as British Thoracic Society Steps 4, 5, and 6).15 
Using evidence from the UK,16 we assumed these cases 
accounted for 15% of total asthma cases younger than 
5 years, 17% aged 5–19 years, 23% aged 20–54 years, and 
43% in those aged 55 years or older.
For HIV/AIDS, we included all populations, including 
those on antiretroviral therapy (ART). We did a sensitivity 
analysis to determine how estimates would change if we 
removed individuals using ART, in the case no additional 
risk of severe COVID-19 was found in individuals on 
ART. We used WHO national estimates for ART coverage 
among those living with HIV/AIDS.17
Estimating individuals at increased risk
We estimated the percentage of country populations at 
increased risk of severe COVID-19 (those with at least 
one underlying condition listed as “at increased risk” in 
guidelines6–8) with and without age standardisation. 
GBD provides prevalence estimates for each disease 
separately, but does not provide the prevalence of people 
who have more than one disease. Diseases can cluster—
for example, if they are causally related. To address this, 
we first calculated e, the expected proportion of 
individuals with at least one COVID-19-related 
condition—assuming no clustering and that the 
prevalences involved are independent (eg, the fact that 
someone has diabetes does not affect their risk of 
getting cancer)—as 1 minus the probability of not 
having a condition in any of the 11 categories ci: 
1 − [1 − p(c1)] × [1 − p(c2)] × [1 − p(c3)] × … × [1 − p(c11)].
We then estimated the proportion P who have at least 
one underlying condition as P = e × r, where r is the ratio 
between the observed and expected percentage of 
individuals with at least one condition. We based r on 
evidence from large cross-sectional multimorbidity 
studies in Scotland18 and southern China19 (appendix 
pp 3–4).
Adjustment for multimorbidity
In addition to providing estimates for r, the studies18,19 in 
Scotland and southern China were used to calculate the 
multimorbidity fraction—ie, the proportion of individuals 
with at least two underlying conditions—among those 
with at least one condition, by age group and sex. For 
these calculations, we used disease categories in the 
two studies that matched as closely as possible to the 
COVID-19-relevant categories defined in our analysis. In 
both studies, this included cardiovascular disease (defined 
as the presence of one or more of coronary heart disease, 
hypertension, cerebrovascular disease, peripheral arterial 
disease, heart failure, or atrial fibrillation), chronic neuro-
logical disorders (defined as one or more of dementia, 
multiple sclerosis, and Parkinson’s disease), and chronic 
respiratory disease (defined as one or both of chronic 
obstructive pulmonary disease and bronchiec tasis). The 
remaining COVID-19-related conditions listed previously 
were counted separately. GBD provides separate estimates 
for hypertensive heart disease and chronic kidney disease 
due to hypertension, but it was not possible to make 
this distinction in the multimorbidity datasets, so all 
hypertension was included in the cardiovascular disease 
category.
Using data from both studies, we calculated pooled 
estimates of the ratio r and the multimorbidity fraction 
by age and sex (appendix pp 3–4) and applied these 
pooled estimates to all countries in the analysis.
Inclusion of older individuals without underlying 
conditions
Some countries have also considered older age as a proxy 
for frailty and thus increased risk of severe COVID-19. 
Although frailty correlates much more closely with mor-
tality than chronological age, there is a well established 
non-linear association between increasing age and frailty.20 
We therefore calculated the number of individuals with-
out an underlying condition that could be considered at 
increased risk because of their age, using age thresholds 
ranging from 50 to 70 years. All age thresholds were 
evaluated in all regions. To calculate the total number 
at increased risk for different age thresholds, we added 
the number of older individuals without underlying 
conditions to our previous estimates of the number of 
individuals with at least one underlying condition.
Estimating individuals at high risk
To aid interpretation of the degree of risk among 
individuals at increased risk, we also estimated the 
number of individuals at high risk, defined as those that 
would require hospital admission if infected, calculated 
using previously estimated age-specific infection–
hospitalisation ratios (IHRs) for COVID-19. This risk 
group includes infections and severe cases in the wider 
population (irrespective of whether they had underlying 
conditions). Thus the high-risk group is not a precise 
subset of the increased-risk group because it includes 
some severe cases without underlying conditions. To 
estimate numbers at high risk, we applied country-level 
UN estimates of the number of individuals alive in each 
5-year age group13 to age-specific IHRs recently estimated 
for mainland China by Verity and colleagues.21 We made 
two adjustments to account for differences between 
IHRs in China and other countries (appendix pp 5–6). 
The first was designed to capture the effect on IHRs of 
For the GBD results tool see 
http://ghdx.healthdata.org/gbd-
results-tool
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national variations in prevalence mix compared with 
China. For each 5-year age group and sex, the prevalence 
rates for each underlying condition were multiplied by 
their respective relative risks (RRs) for hospitalisation 
of 3·0 for chronic kidney disease, diabetes, and 
cardiovascular disease and of 1·5 for the eight other 
Africa (n=1338·8 
million)
Asia  
(n=4632·9 
million)
Europe 
(n=747·1 
million)
Latin America and 
the Caribbean 
(n=652·2 million)
Northern America 
(n=368·7  
million)
Oceania 
(n=41·9 
million)
Global 
(n=7781·7 
million)
Population by number of conditions
No conditions
<15 years 519·2 (39%) 1042·4 (22%) 117·2 (16%) 151·6 (23%) 65·0 (18%) 9·5 (23%) 1905·0 (24%)
15–49 years 533·6 (40%) 1985·9 (43%) 274·3 (37%) 291·6 (45%) 146·6 (40%) 16·7 (40%) 3248·8 (42%)
50–54 years 24·8 (2%) 184·3 (4%) 33·4 (4%) 22·9 (4%) 14·5 (4%) 1·5 (4%) 281·5 (4%)
55–59 years 17·6 (1%) 136·9 (3%) 29·4 (4%) 18·0 (3%) 12·9 (3%) 1·3 (3%) 216·1 (3%)
60–64 years 11·6 (<1%) 95·8 (2%) 22·6 (3%) 12·5 (2%) 10·0 (3%) 1·0 (2%) 153·6 (2%)
65–69 years 7·0 (<1%) 69·5 (1%) 16·0 (2%) 8·3 (1%) 6·7 (2%) 0·7 (2%) 108·2 (1%)
≥70 years 6·6 (<1%) 73·8 (2%) 23·2 (3%) 9·9 (2%) 8·5 (2%) 1·0 (2%) 122·9 (2%)
All ages 1120·5 (84%) 3588·5 (77%) 516·1 (69%) 514·8 (79%) 264·4 (72%) 31·8 (76%) 6036·0 (78%)
One condition only
<15 years 19·9 (1%) 43·5 (<1%) 2·7 (<1%) 4·0 (<1%) 1·6 (<1%) 0·3 (<1%) 71·9 (<1%)
15–49 years 100·8 (8%) 367·6 (8%) 49·1 (7%) 45·1 (7%) 19·7 (5%) 2·9 (7%) 585·2 (8%)
50–54 years 13·4 (1%) 82·3 (2%) 14·1 (2%) 10·3 (2%) 6·6 (2%) 0·6 (1%) 127·3 (2%)
55–59 years 12·2 (<1%) 77·4 (2%) 17·3 (2%) 10·4 (2%) 8·4 (2%) 0·7 (2%) 126·4 (2%)
60–64 years 10·5 (<1%) 68·6 (1%) 18·3 (2%) 9·5 (1%) 9·2 (3%) 0·7 (2%) 116·8 (2%)
65–69 years 8·3 (<1%) 61·2 (1%) 17·5 (2%) 8·1 (1%) 8·6 (2%) 0·6 (2%) 104·3 (1%)
≥70 years 11·3 (<1%) 92·1 (2%) 39·4 (5%) 14·5 (2%) 17·4 (5%) 1·4 (3%) 176·1 (2%)
All ages 176·4 (13%) 792·6 (17%) 158·4 (21%) 102·0 (16%) 71·6 (19%) 7·3 (17%) 1308·2 (17%)
Multiple (two or more) conditions
<15 years 1·3 (<1%) 2·8 (<1%) 0·2 (<1%) 0·3 (<1%) 0·1 (<1%) 0·0 (<1%) 4·6 (<1%)
15–49 years 14·1 (1%) 55·1 (1%) 7·9 (1%) 6·9 (1%) 3·2 (<1%) 0·4 (1%) 87·7 (1%)
50–54 years 3·8 (<1%) 23·3 (<1%) 4·0 (<1%) 2·9 (<1%) 1·9 (<1%) 0·2 (<1%) 36·0 (<1%)
55–59 years 4·3 (<1%) 27·1 (<1%) 6·0 (<1%) 3·7 (<1%) 3·0 (<1%) 0·2 (<1%) 44·3 (<1%)
60–64 years 4·6 (<1%) 29·8 (<1%) 8·0 (1%) 4·1 (<1%) 4·0 (1%) 0·3 (<1%) 50·8 (<1%)
65–69 years 4·5 (<1%) 33·1 (<1%) 9·5 (1%) 4·4 (<1%) 4·6 (1%) 0·3 (<1%) 56·4 (<1%)
≥70 years 9·3 (<1%) 80·6 (2%) 37·1 (5%) 13·2 (2%) 16·0 (4%) 1·3 (3%) 157·6 (2%)
All ages 41·9 (3%) 251·8 (5%) 72·7 (10%) 35·5 (5%) 32·8 (9%) 2·8 (7%) 437·4 (6%)
Population at increased risk of severe COVID-19
People with at least 
one condition (all 
ages), assuming no 
age-based threshold
218·3 (16%) 1044·4 (23%) 231·0 (31%) 137·4 (21%) 104·4 (28%) 10·1 (24%) 1745·6 (22%)
Older people with no conditions*
≥50 years 67·7 (5%) 560·3 (12%) 124·6 (17%) 71·5 (11%) 52·7 (14%) 5·5 (13%) 882·3 (11%)
≥55 years 42·9 (3%) 375·9 (8%) 91·2 (12%) 48·7 (7%) 38·2 (10%) 4·0 (9%) 600·8 (8%)
≥60 years 25·2 (2%) 239·1 (5%) 61·8 (8%) 30·7 (5%) 25·3 (7%) 2·6 (6%) 384·8 (5%)
≥65 years 13·6 (1%) 143·2 (3%) 39·3 (5%) 18·2 (3%) 15·3 (4%) 1·6 (4%) 231·2 (3%)
≥70 years 6·6 (<1%) 73·8 (2%) 23·2 (3%) 9·9 (2%) 8·5 (2%) 1·0 (2%) 122·9 (2%)
People with at least one condition plus older people with no conditions*
≥50 years 286·0 (21%) 1604·7 (35%) 355·7 (48%) 209·0 (32%) 157·1 (43%) 15·6 (37%) 2627·9 (34%)
≥55 years 261·2 (20%) 1420·4 (31%) 322·3 (43%) 186·1 (29%) 142·6 (39%) 14·0 (34%) 2346·5 (30%)
≥60 years 243·5 (18%) 1283·5 (28%) 292·8 (39%) 168·1 (26%) 129·7 (35%) 12·7 (30%) 2130·4 (27%)
≥65 years 231·9 (17%) 1187·7 (26%) 270·3 (36%) 155·6 (24%) 119·7 (32%) 11·7 (28%) 1976·8 (25%)
≥70 years 224·9 (17%) 1118·2 (24%) 254·2 (34%) 147·3 (23%) 112·9 (31%) 11·0 (26%) 1868·6 (24%)
Data are number of individuals in millions (percentage of total population of the region). *Older people with no conditions could be considered at increased risk by virtue of 
age alone.
Table 1: Number of individuals in millions at increased risk of severe COVID-19 illness by age, number of conditions, region, and age threshold
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conditions. The totals were then summed across all 
11 conditions and added to the proportion of individuals 
without underlying conditions, to create a risk score for 
each 5-year age group. IHRs were then multiplied by the 
ratio of the risk score for the country of interest and 
China. The RRs used were based on studies that allowed 
comparison of hospitalised and non-hospitalised people 
with COVID-19 and were assumed to be the same for 
every country (appendix pp 5–10). The second was to 
adjust for infections in given age groups being more 
severe in higher mortality settings, using differences in 
age-specific life expectancy as a proxy, multiplying the 
IHR for each country by the ratio of age-specific life 
expectancy between China and that country.
Sex is not included in current guidelines but studies 
have shown an association between male sex and hospital 
admission. We therefore assumed males were twice as 
likely to be at high risk in all age groups (appendix p 8).22–24
Uncertainty
For numbers at increased risk, we generated uncertainty 
intervals (UIs) by running low and high scenarios 
using the lower and upper 95% confidence limits for 
age-specific and sex-specific country population size, 
disease prevalences, and multimorbidity fractions. The 
UN population estimates for 2020 are not provided 
with 95% CIs, so we generated 95% CIs that were 
consistent with the 95% UIs around the GBD 2017 
population estimates.25 Within our low and high 
scenarios, we also varied r, the ratio between the 
observed and expected percentage of individuals with at 
least one condition, in a range of 0·7 to 1·0, informed 
by the multimorbidity studies.18,19 We ran a jack-knife 
analysis to show the influence of each underlying 
condition on the results by excluding each of the 
conditions, one at a time.
For estimates of numbers at high risk, we generated 
UIs using the low and high credible interval values of the 
IHRs reported by Verity and colleagues21 and the low and 
high 95% confidence limits for the country population 
size. We also ran several scenarios to assess the influence 
of our country-specific adjustments for underlying 
conditions and age-based frailty, and the RRs associated 
with each condition, ranging RRs from 1 to 10 for each 
individual condition (appendix pp 11–12).
All analyses are provided in an Excel spreadsheet tool. 
The tool can be used for rapid assessment and 
visualisation of the estimated number and percentage of 
country populations targeted under different shielding 
policies.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all of the data and the final responsibility to submit for 
publication.
Results
We estimated that 1·7 billion (UI 1·0–2·4) individuals, 
comprising 22% (15–28) of the global population, have at 
least one underlying condition that could increase their 
risk of severe COVID-19 (table 1; table 2; appendix 
pp 13–14). This value does not include older individuals 
Increased risk High risk
Number in 
millions (UI*)
Percentage 
(UI*)
Number 
per 
population
Number in 
millions (UI*)
Percentage 
(UI*)
Number 
per 
population
Both sexes combined
All ages 1746 
(1032–2398)
22% (15–28) 1/4·5 349 (186–787) 4% (3–9) 1/22·3
<20 years 116 (50–167) 4% (2–6) 1/22·4 3 (1–7) 0% (0–0) 1/916·4
20–29 years 134 (70–198) 11% (7–15) 1/8·9 16 (9–37) 1% (1–3) 1/73·6
30–39 years 220 (122–320) 19% (12–25) 1/5·2 38 (20–87) 3% (2–7) 1/30·0
40–49 years 279 (163–392) 29% (19–36) 1/3·5 50 (27–114) 5% (3–11) 1/19·2
50–54 years 163 (98–225) 37% (25–46) 1/2·7 34 (18–76) 8% (4–15) 1/13·2
55–59 years 171 (104–230) 44% (30–54) 1/2·3 41 (22–92) 11% (6–21) 1/9·5
60–64 years 168 (104–224) 52% (36–63) 1/1·9 39 (21–87) 12% (7–25) 1/8·3
65–69 years 161 (101–212) 60% (42–71) 1/1·7 41 (22–92) 15% (9–31) 1/6·6
≥70 years 334 (219–429) 73% (53–85) 1/1·4 87 (47–196) 19% (11–39) 1/5·2
Females
All ages 907 (538–1242) 24% (16–29) 1/4·3 123 (66–278) 3% (2–7) 1/31·3
<20 years 58 (26–83) 5% (2–6) 1/21·7 1 (0–2) 0% (0–0) 1/1390·6
20–29 years 67 (35–99) 12% (7–15) 1/8·5 5 (3–12) 1% (1–2) 1/111·3
30–39 years 111 (62–161) 20% (12–26) 1/5·1 12 (7–28) 2% (1–5) 1/45·1
40–49 years 141 (82–198) 29% (19–37) 1/3·4 17 (9–38) 3% (2–7) 1/28·9
50–54 years 82 (49–114) 37% (25–46) 1/2·7 11 (6–25) 5% (3–10) 1/19·8
55–59 years 86 (52–116) 44% (30–54) 1/2·3 14 (7–31) 7% (4–14) 1/14·2
60–64 years 86 (53–114) 52% (36–63) 1/1·9 13 (7–30) 8% (5–17) 1/12·3
65–69 years 84 (53–111) 60% (42–71) 1/1·7 15 (8–33) 10% (6–21) 1/9·7
≥70 years 191 (126–246) 74% (54–86) 1/1·4 35 (19–79) 14% (8–28) 1/7·4
Males
All ages 838 (494–1156) 21% (14–27) 1/4·7 225 (120–509) 6% (3–12) 1/17·4
<20 years 58 (25–84) 4% (2–6) 1/23·1 2 (1–5) 0% (0–0) 1/694·6
20–29 years 66 (34–99) 11% (6–15) 1/9·2 11 (6–25) 2% (1–4) 1/55·8
30–39 years 109 (61–159) 19% (12–25) 1/5·4 26 (14–59) 4% (3–9) 1/22·6
40–49 years 138 (81–194) 28% (18–36) 1/3·5 34 (18–77) 7% (4–14) 1/14·5
50–54 years 81 (49–112) 36% (25–46) 1/2·7 22 (12–51) 10% (6–21) 1/9·9
55–59 years 84 (52–114) 44% (30–54) 1/2·3 27 (14–61) 14% (8–29) 1/7·1
60–64 years 82 (51–109) 52% (36–63) 1/1·9 25 (13–57) 16% (10–33) 1/6·2
65–69 years 77 (49–101) 60% (42–71) 1/1·7 26 (14–59) 21% (12–42) 1/4·9
≥70 years 143 (93–184) 72% (53–85) 1/1·4 52 (28–116) 26% (16–54) 1/3·8
Increased risk is defined as individuals with at least one condition listed in guidelines. High risk is defined as individuals 
with at least one condition who would require hospitalisation if infected. UI=uncertainty interval. CrI=credible interval. 
*For numbers at increased risk, the low estimates were based on a scenario assuming the lower 95% CI values for the 
age-sex-specific population estimates, disease prevalence rates, and multimorbidity fraction, and assuming r=0·7. The 
high estimates were based on the upper 95% CI values of the same parameters and assume r=1·0. For the numbers at 
high risk, the low estimates were based on a scenario assuming the lower 95% CI values for the age-sex-specific 
population estimates and lower 95% CrI values published by Verity and colleagues21 for infection–hospitalisation ratios 
in mainland China. The high estimates are based on the higher 95% CI values for the age-sex-specific population 
estimates and higher 95% CrI values published by Verity and colleagues.21
Table 2: Global number and percentage of individuals at increased risk and high risk of severe COVID-19 
by age and sex
For the spreadsheet tool see 
https://cmmid.github.io/topics/
covid19/Global_risk_factors.
html
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without underlying conditions. The prevalence of one or 
more conditions was approximately 10% by age 25 years, 
33% by 50 years, and 66% by 70 years, and similar for 
males and females (figure 1). The most prevalent 
conditions in those aged 50 years or older were chronic 
kidney disease, cardiovascular disease, chronic respiratory 
disease, and diabetes. These were also the most influential 
when conditions were removed from the analysis one at 
time (appendix p 15).
Based on crude proportions without age standardi-
sation, the share of the population at risk ranged from 
16% in Africa to 31% in Europe, consistent with the age 
profiles of the regions (table 1; figures 2, 3, 4). The share 
of the population at increased risk was highest in 
countries with older populations (eg, Japan, Puerto Rico, 
and most European countries), African countries with 
high HIV/AIDS prevalence (eg, eSwatini and Lesotho), 
and small island nations with high diabetes prevalence 
(eg, Fiji and Mauritius).
In African countries with high HIV prevalence, 
excluding the population on ART notably reduced the at-
risk proportion: from 29% to 19% in eSwatini, 27% to 20% 
in Botswana, 30% to 24% in Lesotho, and 27% to 23% in 
South Africa.
We estimated that 23% (UI 15–29) of the global working 
age population (15–64 years) have at least one underlying 
condition. Chronic kidney disease and diabetes were the 
most common conditions in this age range (figure 2).
Among the 1·7 billion individuals estimated to be at 
increased risk, we estimated that 0·4 billion (UI 0·2–0·7) 
individuals—6% (3–8) of the global population—are 
living with two or more conditions relevant to COVID-19 
outcomes (table 1; figure 2; appendix pp 13–14). As 
expected, this proportion was higher in regions with an 
older age profile, such as Europe and Northern America. 
Our assumption that males were twice as likely to be at 
high risk than females across all ages means that males 
represent a larger share of the numbers at high risk; there 
were approximately twice the number of males at high 
risk than females in all age groups younger than 
65 years, with this ratio becoming less marked in older 
age groups where males are less represented in the 
general population (figure 2).
If individuals aged 70 years or older without an 
underlying condition are considered at risk solely 
because of their age, then the share of the global 
population at risk increases from 22% to 24% (UI 18–29; 
table 1). If all individuals aged 50 years or older without 
an underlying condition are included, then the share of 
the global population at risk increases to 34% (UI 30–37; 
table 1), but this proportion varies considerably by 
region.
We estimated that 349 million (UI 186–787) 
people—4% (3–9) of the global population—are at high 
risk of severe COVID-19 and would require hospital 
admission if infected (table 2; figures 2, 3, 4). The 
proportion of individuals at high risk in each age group 
ranged from approximately one in every 900 individuals 
younger than 20 years to one in every five individuals 
aged 70 years or older (table 2). Age-specific risks for 
each country are available in the spreadsheet tool, and 
provide more insight into the actual level of risk within 
specific age groups. For example, age-specific risks in 
eSwatini were more than double those in New Zealand 
in nearly all age groups (age-standardised share of the 
population at high risk of 8% vs 3%; appendix p 16), 
despite both countries having a very similar share of the 
population at high risk based on crude percentages of 
the total population at risk (both 5%; figure 3).
Adjustments for national mix of underlying conditions 
and age-based frailty were influential in Africa (40% 
increase in the number at high risk), but less influential 
in other UN regions (≤11% change in the number at 
high risk). In Africa, the share of the population at high 
risk was 2·2% (30 million) without adjustment, 2·7% 
(36 million) with adjustment for underlying conditions 
and 3·1% (42 million) with adjustment for both 
underlying conditions and age-based frailty (appendix 
p 12). Also, the share of the population at high risk 
increased from 3·1% (42 million) to 3·7% (49 million) 
when the RR for HIV was increased from 1·5 to 10·0 
(appendix p 12). However, the proportions of the 
population at increased and high risk estimated for 
Africa are lower than in other regions, driven by 
demographics and strong association between severe 
COVID-19 and age, even after adjusting for underlying 
conditions and age-based frailty (figure 4). This should 
not be interpreted as Africa having lower risks of severe 
COVID-19 disease at equivalent ages than elsewhere, but 
rather Africa having a lower share of its population 
living in the oldest (and highest risk) age groups. Indeed, 
age-standardised rates (assuming each country has the 
same population structure) show a broadly similar share 
of the population at risk in most parts of the world, 
although African countries with high HIV prevalence 
and small island nations with high prevalence of 
diabetes still have a high share of the population at risk 
(appendix p 16).
Discussion
Based on current guidelines, we estimate that about one 
in five individuals worldwide has an underlying condition 
that could put them at increased risk of severe COVID-19 
if infected, ranging from less than 5% of those younger 
than 20 years to more than 66% of those aged 70 years 
Figure 1: Global proportion of individuals with at least one underlying 
condition, by age and sex, and global prevalence of each underlying 
condition by age
Grey lines represent individual countries and show variation around the global 
estimates (black lines). We excluded latent tuberculosis from our analysis but 
include it here to show the extent of overall tuberculosis that was excluded.
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Figure 2: Number and 
percentage of population at 
increased risk and high risk 
of severe COVID-19 by age 
and region; and distribution 
of underlying conditions by 
age and region
Each row of graphs presents 
data for a UN geographical 
region. The first and second 
columns show the number of 
individuals and percentage 
share of the population, 
respectively, in each risk group 
by age, with those at high risk 
divided into females and 
males. The third column shows 
the distribution of the 
11 underlying conditions by 
age, including multimorbidity 
as a separate category. 
*Excludes latent infections. 
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or older. However, for many of these individuals, their 
condition might not be diagnosed or known to the health 
system, or their increased risk could be quite modest. 
Indeed, we estimate that fewer individuals (about one 
in 20) would actually require hospital admission if 
infected, ranging from less than 1% of those younger than 
20 years to nearly 20% of people aged 70 years or older, 
rising to more than 25% in males. Whether or not these 
Figure 3: Proportion of 
population at increased risk 
and high risk of severe 
COVID-19 by country and 
region
The total length of each bar 
represents the share of the 
population at increased risk 
(ie, those with at least one 
condition listed as at increased 
risk in current guidelines); this 
excludes individuals 
considered to be at increased 
risk by virtue of their age 
alone. The darker bars 
represent the share of the 
population at high risk (ie, 
those that would require 
hospital admission if infected), 
with thin bars representing 
uncertainty intervals. Here, the 
population at risk is not age 
standardised. Thus, differences 
between countries are driven 
by differences in the 
population structure, as well 
as differences in risk at 
equivalent ages. This is 
appropriate when calculating 
the number and percentage of 
country populations that 
might need to be shielded or 
vaccinated. Another version of 
this figure shows the age-
standardised population at 
risk (assuming the same 
population structure in each 
country), and thus allows 
more direct comparison of the 
risk at equivalent ages in 
different countries (appendix 
p 16).
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individuals are actually infected, and whether or not they 
receive hospital care if their infection is severe, is beyond 
the scope of this analysis.
Recent estimates from the UN Economic Commission 
for Africa suggest that an unmitigated pandemic could 
lead to a substantial proportion of the African continent 
Figure 4: Proportion of population at increased risk and high risk of severe COVID-19 by country
For age-standardised estimates, see appendix (p 16).
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being infected and 23 million severe cases of COVID-19 
requiring hospitalisation.26 Our estimates for Africa, 
based on the same IHRs estimated for mainland China 
by Verity and colleagues,21 were higher (42 million vs 
23 million), reflecting important adjustments for 
underlying conditions and age-based frailty. However, 
even after these adjustments, the total share of the 
population at high risk is still lower in Africa than in 
Europe (3·1% vs 6·5%). This evidence will need to be 
carefully communicated to policy makers to avoid 
complacency about the risk in Africa. First, the lower 
share of the population at risk simply reflects the much 
younger populations of countries in Africa compared 
with Europe, and therefore masks the fact that age-
specific risks in African countries tend to be similar or 
higher than age-specific risks in European countries 
(appendix p 16). Second, a much higher proportion of 
severe cases are likely to be fatal in Africa than in Europe, 
and disruption to health systems could lead to substantial 
mortality from non-COVID-19 diseases.
If a safe and effective vaccine is produced, then our 
estimates provide an indication of the volumes that would 
be required for vaccination of at-risk individuals globally. 
In the absence of a vaccine, at-risk individuals might need 
to be shielded by more intensive physical distancing 
measures than individuals in the wider population. This 
approach could be especially important at times and places 
where health systems risk being overwhelmed by cases. At 
a minimum, timely information should be provided to 
com munities about who is at increased risk according to 
current guidelines. Simple tools or classifications could 
also be developed to help individuals to understand their 
degree of risk on the basis of their individual character-
istics.27 Improved population-based screening for high-risk 
conditions could also be considered. Among those who are 
identified, govern ments will rely heavily on their adherence 
to guidelines, such as increased hygiene, physical isolation, 
and use of home-delivered food and medical care.6 Other 
infection control measures include provision of personal 
protective equipment and intensive testing of health-care 
and social care workers in maxi mum contact with at-risk 
individuals. Incentives could be introduced to encourage 
at-risk individuals to reduce or abstain from exposure at 
work places, or relocate to dedicated safe zones.28 There is 
also growing evidence in support of face masks as a means 
to prevent transmission by those wearing them.29 If proven 
to be effective, or if other measures emerge,30 this could 
also be a practical way of reducing exposure among those 
who are unable to avoid contact with others, such as daily 
wage earners or people living with (or caring for) less 
vulnerable individuals.31
Our estimates of the number of individuals at high risk 
included adjustments for the prevalence and mix 
of underlying conditions in different countries. This 
required estimates of the strength of association between 
each of the 11 underlying conditions and COVID-19 
hospital admission. We ran scenarios with different RRs, 
informed by the few studies that allowed comparison with 
a control group that was not hospitalised. How-
ever, the true strength of association is uncertain and 
likely to vary across settings. We estimate that a very 
low proportion of younger individuals (about one in 
700 males and one in 1400 females aged <20 years) will 
develop severe illness if infected. These estimates rely 
on IHRs from Verity and colleagues,21 which assume the 
same rate of infection in all age groups. However, younger 
individuals might be less likely to be infected than 
adults,10,32 and consequently could have a higher probability 
of severe disease on infection than estimated by Verity and 
colleagues.33 In either scenario, the absolute risk of severe 
disease should be low in younger individuals, but more 
evidence is needed on the characteristics of younger 
individuals that develop severe symptoms so they can be 
identified and shielded effectively.
Our estimates of the number of individuals at high risk 
in Africa were sensitive to the RR assumed for HIV/AIDS. 
It is not yet known whether those with HIV are at increased 
risk of severe disease with COVID-19.34 Although it has 
been shown that widespread introduction of ART reduced 
the risk of hospitalisation and death associated with 
seasonal influenza,35 a substantial proportion of those on 
ART remain somewhat immuno compromised.36,37 Recent 
evidence from South Africa has shown that individuals 
living with HIV have an eight times higher risk of 
pneumonia hospitalisation associated with seasonal 
influenza and a three times higher risk of pneumonia 
death.38 Until more evidence emerges, it might be 
necessary to include individuals with HIV in shielding 
strategies, irrespective of ART status, with priority given to 
those not yet receiving treatment.39
We included underlying conditions that were listed in 
any of the guidelines (WHO, the UK, and the USA) and 
available in GBD 2017. Risk factors included in guidelines 
but not in GBD (eg, body-mass index [BMI] ≥40 kg/m²) 
were excluded, along with possible risk factors not 
currently included in guidelines (eg, BMI ≥30 kg/m², 
ethnicity, and smoking). However, many of these risk 
factors do not have baseline prevalence data available for 
188 countries by age (in 5-year age groups) and sex. 
Including other risk factors would increase the numbers 
at increased risk, but there is likely to be substantial 
overlap with these factors and the underlying conditions 
already included in the analysis. As our understanding of 
COVID-19 evolves, guidelines will need to be updated, 
and baseline prevalence data will need to be improved, 
particularly on risk factors. Multivariable analyses are 
emerging on the risk of death among those already 
admitted to hospital,24 but information about the risk of 
severe disease (ie, requiring hospital admission) among 
those infected is scarce because very few studies have 
included patients with COVID-19 who were not admitted 
to hospital.23
We estimated a similar number of males and females 
to be at increased risk but assumed males were twice as 
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likely to be at high risk. This is consistent with an 
increasing role of male sex as the severity of COVID-19 
increases.40 Research in mice infected with severe acute 
respiratory syndrome coronavirus also found an 
increased male susceptibility mediated by differences in 
oestrogen receptor signalling,41 while others have noted 
the concentration of genes involved in the immune 
system on the X chromosome.42 This is clearly a priority 
for further research.
The association between the prevalence of underlying 
conditions and other national characteristics, such as 
economic development, is complex. The prevalence of 
many of these conditions, except perhaps HIV/AIDS, 
reflects the epidemiological transition43 but survival with 
these conditions might reflect the performance of the 
health system.44 Hence, it is important to look at the data 
for each country, which goes beyond what we can report 
in this Article. Our spreadsheet tool can be used to 
estimate the number and percentage of country 
populations targeted under different shielding policies. 
This allows different health conditions to be included or 
excluded, different age thresholds to be assessed, and 
different choices about key assumptions—eg, estimates 
of the ratio r and the multimorbidity fraction by age. The 
spreadsheet can also be updated with alternative sources 
of prevalence data if preferred, and specific conditions 
added or removed as more evidence emerges. A recent 
analysis from Sweden45 provides an opportunity to 
evaluate our method. By applying our adjustments for 
clustering to the prevalence data reported in the Swedish 
study (based on electronic health records), we were able 
to reproduce the same percentage share of the population 
at increased risk as that reported in the study.
Our estimates of the share of the population at increased 
risk are based on prevalence estimates extracted from 
GBD.12 Because GBD produces internally comparable 
estimates for a comprehensive list of diseases by age, sex, 
and country, these estimates are well suited to our analysis. 
GBD prevalence estimates are likely to be higher than 
prevalence estimated from national databases because 
they aim to capture cases that might be undiagnosed or 
not severe enough to be included in electronic health 
records. For example, more than half of the chronic kidney 
disease cases included in GBD prevalence estimates 
represent early-stage disease (stage 1 or 2), which is 
common and rarely has symptoms.46 Several other under-
lying conditions estimated by GBD are also likely to 
represent cases that are undiagnosed or not recorded in 
national databases. In a cross-sectional study in England, 
more than 20% of diabetes was undiagnosed in all age 
groups older than 25 years,47 and in lower-income settings, 
this proportion is likely to be much higher.48
While our analysis provides numbers of people who 
could benefit from shielding due to underlying 
conditions, in practice, the low coverage of diagnosis and 
treatment for many chronic conditions in low-income 
settings means that age-based thresholds could play a 
key role. However, the choice of age threshold needs to 
be carefully balanced against the proportion of the 
working age population affected and the adverse mental 
health consequences that might be associated with long 
periods of isolation. Our analysis found that around one 
in five individuals in the working age range had at least 
one underlying condition relevant to COVID-19 severity. 
If implemented, shielding of at-risk individuals is likely 
to be required for several months. This could have a 
substantial impact on working-age people if they and 
their household contacts are less economically active for 
longer than the general population.
We used data from two large studies to adjust for 
multimorbidity. Both studies could have underestimated 
the prevalence of some conditions and therefore the extent 
of multimorbidity, although in Scotland18 most of the 
included conditions were well recorded in routine health 
care, and in the southern China study,19 under lying 
conditions were well communicated to patients, with 
information from a community household survey following 
a standard protocol. However, these studies cannot capture 
the global diversity of patterns of multimorbidity, which 
will differ in regions where, for example, there are high 
prevalences of HIV or sickle cell disorders.
With physical distancing measures of varying intensity 
in place worldwide, and substantial uncertainty about 
the transmissibility of the virus in different contexts, 
the results of any attempt to calculate the number of 
individuals that will eventually be infected in different 
countries will be highly uncertain. Nonetheless, we hope 
our estimates will provide useful a starting point for 
considering the number of individuals that might need 
to be shielded or vaccinated as the global COVID-19 
pandemic unfolds.
Contributors
AC and RME conceived the idea for the study. AC developed the 
spreadsheet tool, did the analyses, produced the tables, and wrote the 
first draft of the manuscript. BG, SWM, and HHXW ran new analyses of 
multimorbidity data from Scotland and southern China. AC, RME, CS, 
MJ, BG, SWM, and HHXW developed methods to adjust for clustering, 
multimorbidity, and underlying conditions. CT helped with general 
consistency checks of GBD prevalence data. RME helped to design the 
spreadsheet tool and produced figures 1, 2, and 3. HPG produced the 
maps in figure 4. All authors have read, contributed to, and approved the 
final version of the manuscript.
Declaration of interests
We declare no competing interests.
Acknowledgments
This work was supported by the Department for International 
Development (DFID) and the Wellcome Trust 221303/Z/20/Z. 
We acknowledge Jennifer Quint (Imperial College London) and 
Arminder Deol and Laurie Tomlinson (London School of Hygiene & 
Tropical Medicine) for providing technical and clinical advice on specific 
diseases. We also acknowledge Ulla Griffiths (Unicef, New York City) 
and Palwasha Anwari (Unicef, Kabul) for providing feedback on the 
spreadsheet. MM is the research director of the European Observatory 
on Health Systems and Policies, a partnership of universities, 
international agencies, universities and foundations. RME acknowledges 
funding from Health Data Research UK (grant MR/S003975/1) and the 
Medical Research Council (MRC; grant MC_PC 19065). HPG 
acknowledges funding from the Department of Health and Social Care 
Articles
e1016 www.thelancet.com/lancetgh   Vol 8   August 2020
using UK Aid funding, managed by the National Institute of Health 
Research (NIHR; grant code ITCRZ 03010). The views expressed in this 
publication are those of the authors and not necessarily those of the 
Department of Health and Social Care. CW-G acknowledges funding 
from the Wellcome Intermediate Clinical Fellowship (201440_Z_16_Z). 
MJ was funded by the NIHR (grants 16/137/109 and NIHR200929), 
Bill & Melinda Gates Foundation (INV-003174), DFID/Wellcome Trust 
(221303/Z/20/Z), and European Commission Horizon 2020 (101003688). 
This research was partly funded by the NIHR using aid from the UK 
Government to support global health research. The views expressed in 
this publication are those of the author(s) and not necessarily those of 
the NIHR, Public Health England, or the UK Department of Health and 
Social Care. AB is supported by the BigData@Heart Consortium, funded 
by the Innovative Medicines Initiative-2 joint undertaking under grant 
agreement number 116074. This joint undertaking receives support from 
the EU’s Horizon 2020 research and innovation programme and 
European Federation of Pharmaceutical Industries and Associations. 
FC acknowledges funding from UK Research and Innovation as part of 
the Global Challenges Research Fund (grant number ES/P010873/1). 
The Centre for the Mathematical Modelling of Infectious Diseases 
COVID-19 working group declare support from the following 
organisations: Bill & Melinda Gates Foundation (grants OPP1183986, 
OPP1191821, INV-003174, OPP1180644, and OPP1184344), Research 
Councils UK (RCUK)/Economic and Social Research Council (ESRC; 
grant ES/P010873/1), UK Public Health Rapid Support Team, NIHR 
Health Protection Research Unit (HPRU) in Modelling Methodology, 
European Commission (grant 101003688), NIHR (grants 
PR-OD-1017–20002, 16/137/109), NIHR EPIC grant (grant 16/137/109), 
European Research Council Starting Grant (action numbers #757688, and 
#757699), Wellcome Trust (grants 210758/Z/18/Z, 208812/Z/17/Z, and 
206250/Z/17/Z), MRC London Intercollegiate Doctoral Training Program 
studentship (grants MR/N013638/1), MRC (grant MR/P014658/1), 
The Nakajima Foundation, The Alan Turing Institute, NIHR HPRU in 
Immunisation (grant HPRU-2012–10096), Global Challenges Research 
Fund for the project RECAP managed through RCUK and ESRC (grant 
ES/P010873/1), and Elrha’s Research for Health in Humanitarian Crises 
(R2HC) Programme. The R2HC Programme is funded by the UK 
Government (DFID), the Wellcome Trust, and the NIHR.
Editorial note: the Lancet Group takes a neutral position with respect to 
territorial claims in published maps and institutional affiliations
References
1 CDC COVID-19 Response Team. Preliminary estimates of the 
prevalence of selected underlying health conditions among patients 
with coronavirus disease 2019—United States, Centers for Disease 
Control and Prevention. February 12–March 28, 2020. 
MMWR Morb Mortal Wkly Rep 2020; 69: 382–86.
2 Instituto Superiore di Sanità, COVID-19 Surveillance Group. 
Characteristics of COVID-19 patients dying in Italy: report based on 
available data on March 20th, 2020. 2020. https://www.epicentro.
iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.
pdf. 2020 (accessed June 8, 2020).
3 Guan WJ, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus 
disease 2019 in China. N Engl J Med 2020; 382: 1708–20.
4 Centre for Evidence-Based Medicine. In patients of COVID-19, what 
are the symptoms and clinical features of mild and moderate cases? 
April 1, 2020. https://www.cebm.net/covid-19/in-patients-of-covid-
19-what-are-the-symptoms-and-clinical-features-of-mild-and-
moderate-case (accessed June 8, 2020).
5 WHO. Global Surveillance for human infection with coronavirus 
disease (COVID-19). March 20, 2020. https://www.who.int/
publications-detail/global-surveillance-for-human-infection-with-
novel-coronavirus-(2019-ncov) (accessed June 8, 2020).
6 Centers for Disease Control and Prevention. People who are at 
higher risk for severe illness. Coronavirus Disease 2019 (COVID-19). 
2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-
precautions/people-at-higher-risk.html (accessed April 1, 2020).
7 Public Health England. Guidance on social distancing for everyone 
in the UK. March 30, 2020. https://www.gov.uk/government/
publications/covid-19-guidance-on-social-distancing-and-for-
vulnerable-people/guidance-on-social-distancing-for-everyone-in-
the-uk-and-protecting-older-people-and-vulnerable-adults (accessed 
April 1, 2020).
8 WHO. COVID-19 and NCDs. Information note on COVID-19 and 
noncommunicable diseases. March 23, 2020. https://www.who.int/
who-documents-detail/covid-19-and-ncds (accessed June 8, 2020).
9 Banerjee A, Pasea L, Harris S, et al. Estimating excess 1-year 
mortality associated with the COVID-19 pandemic according to 
underlying conditions and age: a population-based cohort study. 
Lancet 2020; 395: 1715–25. 
10 Davies N, Klepac P, Liu Y, et al. Age-dependent effects in the 
transmission and control of COVID-19 epidemics. medRxiv 2020; 
published online March 27. DOI:10.1101/2020.03.24.20043018 
(preprint).
11 WHO. Taxonomy and glossary of public health and social measures 
that may be implemented to limit the spread of COVID-19. April 28, 
2020. https://www.who.int/emergencies/diseases/novel-
coronavirus-2019/phsm (accessed June 8, 2020).
12 GBD 2017 Disease and Injury Incidence and Prevalence 
Collaborators. Global, regional, and national incidence, prevalence, 
and years lived with disability for 354 diseases and injuries for 
195 countries and territories, 1990–2017: a systematic analysis for 
the Global Burden of Disease Study 2017. Lancet 2018; 
392: 1789–858.
13 UN Population Division. UNPOP (2019 revision) estimates of 
population by single calendar year (2020), age, sex and country. 
https://population.un.org/wpp/Download/Standard/Interpolated/ 
(accessed April 1, 2020).
14 UN Department of Economic and Social Affairs. Locations. 2019. 
https://population.un.org/wpp/Download/Metadata/
Documentation (accessed June 8, 2020). 
15 British Thoracic Society. British guideline on the management of 
asthma. Quick reference guide. Revised September, 2016. https://
www.brit-thoracic.org.uk/document-library/guidelines/asthma/
btssign-asthma-guideline-quick-reference-guide-2016 (accessed 
June 8, 2020).
16 Bloom CI, Nissen F, Douglas IJ, Smeeth L, Cullinan P, Quint JK. 
Exacerbation risk and characterisation of the UK’s asthma 
population from infants to old age. Thorax 2018; 73: 313–20.
17 WHO. Antiretroviral therapy coverage estimates by country. https://
apps.who.int/gho/data/node.main.626?lang=en. Sept 12, 2019. 
(accessed June 8, 2020).
18 Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. 
Epidemiology of multimorbidity and implications for health care, 
research, and medical education: a cross-sectional study. Lancet 
2012; 380: 37–43.
19 Wang HH, Wang JJ, Wong SY, et al. Epidemiology of 
multimorbidity in China and implications for the healthcare 
system: cross-sectional survey among 162,464 community 
household residents in southern China. BMC Med 2014; 12: 188.
20 Romero-Ortuno R, Kenny RA. The frailty index in Europeans: 
association with age and mortality. Age Ageing 2012; 41: 684–89.
21 Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of 
coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 
2020; 20: 669–77.
22 Docherty AB, Harrison EM, Green CA, et al. Features of 16,749 
hospitalised UK patients with COVID-19 using the ISARIC WHO 
Clinical Characterisation Protocol. medRxiv 2020; published online 
April 28. DOI:10.1101/2020.04.23.20076042 (preprint).
23 Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital 
admission and critical illness among 5279 people with coronavirus 
disease 2019 in New York City: prospective cohort study. BMJ 2020; 
369: m1966. 
24 Williamson E. Alex J Walker, Krishnan J Bhaskaran, et al. 
OpenSAFELY: factors associated with COVID-19-related hospital 
death in the linked electronic health records of 17 million adult 
NHS patients. The OpenSAFELY Collaborative. medRxiv 2020; 
published online May 7. DOI:10.1101/2020.05.06.20092999 
(preprint).
25 Institute for Health Metrics and Evaluation. Global Burden of 
Disease Study 2017 (GBD 2017) population estimates 1950–2017. 
March 30, 2019. http://ghdx.healthdata.org/record/ihme-data/gbd-
2017-population-estimates-1950-2017 (accessed June 8, 2020).
26 UN Economic Commission for Africa. COVID-19 in Africa: 
protecting lives and economies. 2020. https://www.uneca.org/
publications/covid-19-africa-protecting-lives-and-economies 
(accessed June 8, 2020).
Articles
www.thelancet.com/lancetgh   Vol 8   August 2020 e1017
27 Dagan N, Barda N, Riesel D, Grotto I, Sadetzki S, Balicer R. A 
score-based risk model for predicting severe COVID-19 infection 
as a key component of lockdown exit strategy. medRxiv 2020; 
pubished online May 23. DOI:10.1101/2020.05.20.20108571 
(preprint).
28 Dahab M, van Zandvoort K, Flasche S, et al. COVID-19 control in 
low-income settings and displaced populations: what can 
realistically be done? March 20, 2020. https://www.lshtm.ac.uk/
newsevents/news/2020/covid-19-control-low-income-settings-and-
displaced-populations-what-can (accessed June 8, 2020).
29 Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the 
novel Wuhan coronavirus (COVID-19) infection: a systematic 
review and meta-analysis. Int J Infect Dis 2020; 94: 91–95.
30 Michie S. Robert West, Amlôt R. Behavioural strategies for reducing 
covid-19 transmission in the general population. March 3, 2020. 
https://blogs.bmj.com/bmj/2020/03/03/behavioural-strategies-for-
reducing-covid-19-transmission-in-the-general-population (accessed 
June 8, 2020).
31 Lloyd-Sherlock P, Ebrahim S, Geffen L, McKee M. Bearing the 
brunt of covid-19: older people in low and middle income countries. 
BMJ 2020; 368: m1052.
32 Viner RM, Mytton OT, Bonell C, et al. Susceptibility to and 
transmission of COVID-19 amongst children and adolescents 
compared with adults: a systematic review and meta-analysis. 
medRxiv 2020; published online May 24. 
DOI:10.1101/2020.05.20.20108126 (preprint).
33 Ayoub HH, Chemaitelly H, Mumtaz GR, et al. Characterizing key 
attributes of the epidemiology of COVID-19 in China: model-based 
estimations. medRxiv 2020; published online April 11. 
DOI:10.1101/2020.04.08.20058214 (preprint).
34 European Aids Clinical Society. EACS & BHIVA statement on risk 
of COVID-19 for people living with HIV (PLWH). April 30, 2020. 
https://www.eacsociety.org/home.html (accessed May 20, 2020).
35 Cohen C, Moyes J, Tempia S, et al. Severe influenza-associated 
respiratory infection in high HIV prevalence setting, South Africa, 
2009–2011. Emerg Infect Dis 2013; 19: 1766–74.
36 Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals 
with low CD4/CD8 ratio despite effective antiretroviral therapy 
exhibit altered T cell subsets, heightened CD8+ T cell activation, 
and increased risk of non-AIDS morbidity and mortality. 
PLoS Pathog 2014; 10: e1004078.
37 Wilson EM, Sereti I. Immune restoration after antiretroviral 
therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev 
2013; 254: 343–54.
38 Academy of Science of South Africa. ASSAf statement on the 
implications of the novel coronavirus (SARS-CoV-2; COVID-19) in 
South Africa. 2020. https://www.assaf.org.za/index.php/about-
assaf/council-members/2-uncategorised/602-assaf-statement-on-
the-implications-of-the-novel-coronavirus-sars-cov-2-covid-19-in-
south-africa (accessed June 8, 2020).
39 BHIVA. Comment from BHIVA and THT on UK Government 
guidance on coronavirus (COVID-19), social distancing to protect 
vulnerable adults and shielding to protect extremely vulnerable 
adults. March 23, 2020. https://www.bhiva.org/comment-from-
BHIVA-and-THT-on-UK-Government-guidance-on-
Coronavirus-COVID-19 (accessed June 8, 2020).
40 Liu W, Tao ZW, Lei W, et al. Analysis of factors associated with 
disease outcomes in hospitalized patients with 2019 novel 
coronavirus disease. Chin Med J (Engl) 2020; 133: 1032–38.
41 Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, 
Perlman S. Sex-based differences in susceptibility to severe acute 
respiratory syndrome coronavirus infection. J Immunology 2017; 
198: 4046–53.
42 Fischer J, Jung N, Robinson N, Lehmann C. Sex differences in 
immune responses to infectious diseases. Infection 2015; 43: 399–403.
43 Omran AR. The epidemiologic transition. A theory of the 
epidemiology of population change. Milbank Mem Fund Q 1971; 
49: 509–38.
44 Fullman N, Yearwood J, Abay SM, et al. Measuring performance on 
the Healthcare Access and Quality Index for 195 countries and 
territories and selected subnational locations: a systematic analysis 
from the Global Burden of Disease Study 2016. Lancet 2018; 
391: 2236–71.
45 Gemes K, Talback M, Modig K, et al. Burden and prevalence of 
prognostic factors for severe covid-19 disease in Sweden. medRxiv 
2020; published online April 11. DOI:10.1101/2020.04.08.20057919 
(preprint).
46 Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national 
burden of chronic kidney disease, 1990–2017: a systematic analysis 
for the Global Burden of Disease Study 2017. Lancet 2020; 
395: 709–33.
47 Moody A, Cowley G, Ng Fat L, Mindell JS. Social inequalities in 
prevalence of diagnosed and undiagnosed diabetes and impaired 
glucose regulation in participants in the Health Surveys for England 
series. BMJ Open 2016; 6: e010155.
48 White LV, Edwards T, Lee N, et al. Patterns and predictors of 
co-morbidities in tuberculosis: a cross-sectional study in the 
Philippines. Sci Rep 2020; 10: 4100.
